Wells Fargo raised the firm’s price target on Alnylam (ALNY) to $287 from $275 and keeps an Equal Weight rating on the shares. The firm says label came in line with its expectations. Maintaining list price adds uncertainty on competitive positioning, but was likely expected by most, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Cautious Outlook on Alnylam Pharma Amid Amvuttra’s FDA Approval and Pricing Concerns
- Buy Recommendation for Amvuttra: Strong Clinical Data and Strategic Market Positioning Drive Growth Potential
- Alnylam’s Amvuttra approved by FDA in cardiomyopathy
- Alnylam trading halted, news pending
- Alnylam Pharma’s Strategic Positioning and Market Opportunities Drive Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com